Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 1;40(19):2174-2175.
doi: 10.1200/JCO.22.00092. Epub 2022 Apr 21.

Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present

Laura Marandino  1 , Daniele Raggi  1 , Andrea Necchi  1 , Massimo Di Maio  1
Affiliations
Comment

Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present

Laura Marandino et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Laura MarandinoResearch Funding: AstraZeneca Andrea NecchiEmployment: BayerStock and Other Ownership Interests: BayerHonoraria: Roche, Merck, AstraZeneca, Janssen, Foundation Medicine, Bristol Myers SquibbConsulting or Advisory Role: Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol Myers Squibb, Rainier Therapeutics, GlaxoSmithKline, FerringResearch Funding: Merck Sharp & Dohme (Inst), AstraZeneca (Inst), Ipsen, Seattle Genetics (Inst)Travel, Accommodations, Expenses: Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, Rainier TherapeuticsOther Relationship: Bayer Massimo Di MaioHonoraria: Pfizer, Takeda, AstraZeneca, Janssen, Eisai, Novartis, Roche, Astellas Pharma, MSD OncologyConsulting or Advisory Role: AstraZeneca, Pfizer, Takeda, Janssen, Eisai, Novartis, Roche, MSD Oncology, AmgenResearch Funding: Tesaro (Inst), GlaxoSmithKline (Inst)No other potential conflicts of interest were reported.

Comment in

  • Reply to L. Marandino et al.
    Stockler MR, Martin AJ, Dhillon HM, Davis ID, Sweeney CJ. Stockler MR, et al. J Clin Oncol. 2022 Jul 1;40(19):2176-2177. doi: 10.1200/JCO.22.00497. Epub 2022 Apr 21. J Clin Oncol. 2022. PMID: 35446681 No abstract available.

Comment on

  • Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Stockler MR, et al. J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20. J Clin Oncol. 2022. PMID: 34928708 Free PMC article. Clinical Trial.

Substances

LinkOut - more resources